Merck KGaA Erbitux Trial Designed With FDA Feedback On ImClone U.S. Trials
Executive Summary
Merck KGaA's Erbitux Phase II trial in colorectal cancer will benefit from FDA feedback on ImClone's earlier U.S. trial designs, ImClone Chief Operating Officer Harlan Waksal said